Display options
Cite
Goldenberg G, Perl M. Actinic keratosis: update on field therapy. J Clin Aesthet Dermatol. 2014;7(10):28-31
Goldenberg, G., & Perl, M. (2014). Actinic keratosis: update on field therapy. The Journal of clinical and aesthetic dermatology, 7(10), 28-31.
Goldenberg, Gary, and Perl, Marcel. "Actinic keratosis: update on field therapy." The Journal of clinical and aesthetic dermatology vol. 7,10 (2014): 28-31.
Goldenberg G, Perl M. Actinic keratosis: update on field therapy. J Clin Aesthet Dermatol. 2014 Oct;7(10):28-31. PMID: 25371768; PMCID: PMC4217291.
Copy Download .nbib Format: NLM
Share it on

J Clin Aesthet Dermatol. 2014 Oct;7(10):28-31.

Actinic keratosis: update on field therapy.

The Journal of clinical and aesthetic dermatology

Gary Goldenberg, Marcel Perl

Affiliations

  1. Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York;
  2. Icahn School of Medicine at Mount Sinai, New York, New York.

PMID: 25371768 PMCID: PMC4217291

Abstract

Actinic keratosis is widely considered a field disease that is rarely limited to a single clinically apparent lesion. Field-directed therapies, such as ingenol mebutate, imiquimod, and photodynamic therapy, aim to treat not only clinically visible lesions, but also subclinical disease that is thought to exist along the same continuum as actinic keratosis and squamous cell carcinoma. These field treatments have shown efficacy compared to placebo as well as in long-term follow-up studies when compared to lesion-directed cryotherapy alone. Field therapy in combination with lesion-directed treatment will allow the practitioner to further optimize efficacy as well as patient preference and convenience. As the incidence of nonmelanoma skin cancer continues to rise, these treatment modalities provide new options to halt the progression of actinic keratosis, and thereby reduce the incidence of nonmelanoma skin cancer and its burden on our healthcare system.

References

  1. Cochrane Database Syst Rev. 2012 Dec 12;12:CD004415 - PubMed
  2. Aust N Z J Surg. 1992 Sep;62(9):697-701 - PubMed
  3. Br J Dermatol. 2007 Dec;157 Suppl 2:34-40 - PubMed
  4. J Invest Dermatol. 2006 Jun;126(6):1251-5 - PubMed
  5. Eur J Dermatol. 2008 Nov-Dec;18(6):651-9 - PubMed
  6. Arch Dermatol. 2010 Mar;146(3):288-93 - PubMed
  7. J Drugs Dermatol. 2012 Dec;11(12):1483-9 - PubMed
  8. J Surg Oncol. 2012 Dec;106(7):811-5 - PubMed
  9. J Clin Invest. 2012 Feb;122(2):464-72 - PubMed
  10. J Invest Dermatol. 2006 Feb;126(2):265-71 - PubMed
  11. J Immunol. 2006 Dec 1;177(11):8123-32 - PubMed
  12. N Engl J Med. 2012 Mar 15;366(11):1010-9 - PubMed
  13. Cancer Res. 2004 Apr 15;64(8):2833-9 - PubMed
  14. Int J Dermatol. 2004 Sep;43(9):687-92 - PubMed
  15. J Drugs Dermatol. 2010 Sep;9(9):1101-8 - PubMed
  16. Drugs. 1999 May;57(5):725-34 - PubMed
  17. Pharmacoeconomics. 2009;27(6):451-64 - PubMed
  18. Cancer. 2009 Jun 1;115(11):2523-30 - PubMed
  19. Br J Dermatol. 2013 Apr;168(4):825-36 - PubMed
  20. Eur J Dermatol. 2009 Jul-Aug;19(4):345-54 - PubMed
  21. Dermatol Surg. 2006 Aug;32(8):1045-9 - PubMed
  22. Br J Dermatol. 2013 Sep;169(3):502-18 - PubMed
  23. Expert Opin Pharmacother. 2009 Dec;10(18):3015-31 - PubMed
  24. Cancer Immunol Immunother. 2008 Aug;57(8):1241-51 - PubMed
  25. Arch Dermatol. 1988 Jan;124(1):72-9 - PubMed
  26. J Am Acad Dermatol. 2009 Aug;61(2):207-15 - PubMed
  27. JAMA Dermatol. 2013 Jun;149(6):666-70 - PubMed
  28. J Clin Aesthet Dermatol. 2013 Feb;6(2):36-43 - PubMed
  29. J Am Acad Dermatol. 2012 Mar;66(3):486-93 - PubMed
  30. Australas J Dermatol. 2009 Feb;50(1):16-22 - PubMed
  31. J Am Acad Dermatol. 2010 Apr;62(4):582-90 - PubMed
  32. J Am Acad Dermatol. 2009 Jun;60(6):934-43 - PubMed

Publication Types